ArticleBMC infectious diseases2026
Undetectable unintegrated HIV-DNA in persons with HIV: frequency and determinants.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundDespite suppressive antiretroviral therapy (ART), HIV-1 persists in infected cells as integrated proviral DNA and as more labile unintegrated DNA forms (uDNA). The presence of uDNA has been proposed as a surrogate marker of recent infection events occurring below the detection limits of plasma HIV-1 RNA assays. The aim of this study was to evaluate the performance of an assay for the quantification of uDNA in peripheral whole blood of people with HIV (PWH), with the intent of identifying individuals with no evidence of recent infection events, defined as undetectable uDNA, and to characterize associated clinical and immunological factors.
methodsTotal and unintegrated HIV-1 DNA were quantified by real-time PCR in whole blood samples from 87 chronically treated PWH. Samples were derived from a real-world, retrospective cohort and reflected the antiretroviral regimens actually received by patients over time. Clinical, virological, and immunological parameters were analyzed in relation to uDNA detectability.
resultsOverall, uDNA was quantifiable in 11/87 (13%) samples, detectable below the assay quantification limit in 52/87 (60%), and undetectable (target not detected) in 24/87 (28%). Undetectable uDNA was associated with higher CD4⁺ T-cell nadir, higher current CD4⁺ T-cell counts, and lower total HIV-1 DNA levels. In multivariable analysis, CD4⁺ T-cell nadir was the only factor independently associated with uDNA undetectability (p = 0.001). Antiretroviral regimen characteristics were not independently associated with uDNA detectability.
conclusionsA substantial proportion of chronically treated PWH exhibited undetectable uDNA in peripheral blood. The uDNA measurement provides complementary information to plasma HIV-1 RNA and CD4⁺ T-cell counts and may help identify individuals with no evidence of recent infection events and higher immunological fitness. These findings support the potential utility of uDNA quantification as a biomarker of HIV-1 reservoir dynamics in real-world clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.